LINEARX

What this means for you

Registered since 25 Oct 2022. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

88130878

Registration number

6885110

Mark type

Stylized text

Filed

25 Sept 2018

Published for opposition

07 May 2019

Registered

25 Oct 2022

Attorney of record

Clay Shorrock

Goods and services

• Class 001 — Chemicals: Biological preparations for use in industry and science; nucleic acid for laboratory use
• Class 005 — Pharmaceuticals: Biological preparations for the treatment of cancer; nucleic acid sequences and chemical reagents for medical and veterinary purposes
• Class 040 — Treatment of materials: Manufacturing of DNA expression vectors for others
• Class 042 — Scientific and technological services: Scientific research; biotechnology research and development; biological research; biomedical research; research and development services in the field of DNA based medications and therapies; DNA expression vector design and development for others; biotech and clinical research and development of DNA based medications and therapies

Owner

• LineaRX, Inc., Stony Brook, NY, US
• LineaRX, Inc., Stony Brook, NY, US
• LineaRX, Inc., Stony Brook, NY, US

Prosecution history

• 25 Oct 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
• 25 Oct 2022 — REGISTERED-PRINCIPAL REGISTER
• 20 Sept 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
• 19 Sept 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
• 12 Aug 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 12 Aug 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 12 Aug 2022 — ASSIGNED TO LIE
• 09 Aug 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 09 Feb 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 09 Feb 2022 — NON-FINAL ACTION E-MAILED
• 09 Feb 2022 — SU - NON-FINAL ACTION - WRITTEN
• 21 Jan 2022 — STATEMENT OF USE PROCESSING COMPLETE
• 03 Jan 2022 — USE AMENDMENT FILED
• 19 Jan 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
• 03 Jan 2022 — TEAS STATEMENT OF USE RECEIVED